Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

An international phase 2 study combining cladribine and cytarabine (Ara-C) was initiated for patients with refractory, risk-organ–positive Langerhans cell histiocytosis (LCH) in 2005. The protocol, comprising at least two 5-day courses of Ara-C (1 g/m(2) per day) plus cladribine (9 mg/m(2) per day)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Donadieu, Jean, Bernard, Frederic, van Noesel, Max, Barkaoui, Mohamed, Bardet, Odile, Mura, Rosella, Arico, Maurizio, Piguet, Christophe, Gandemer, Virginie, Armari Alla, Corinne, Clausen, Niels, Jeziorski, Eric, Lambilliote, Anne, Weitzman, Sheila, Henter, Jan Inge, Van Den Bos, Cor
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2015
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624454/
https://ncbi.nlm.nih.gov/pubmed/26194764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-635151
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items